
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
The Effect of Melatonin as an Adjuvant Therapy on COVID-19: A Randomized Clinical Trial
17 Pages Posted: 1 Jul 2021
More...Abstract
Background: Melatonin is secreted by the pineal gland and has antioxidant and anti-inflammatory properties. So, it is proposed to be effective in the management of Coronavirus disease 2019 (COVID-19). This study aimed to evaluate the effect of melatonin as adjunctive therapy for the treatment of hospitalized patients with mild to moderate COVID-19.MethodsIn this double-blind randomized placebo controlled clinical trial, 81 mild to moderate hospitalized COVID-19 patients with inclusion criteria were randomly divided to treatment (n=42) group to receive melatonin tablet 3 mg, three times daily for 2 weeks or placebo (n=39) group. Patients’ symptoms and laboratory data were assessed at baseline and during the follow-up period and compared between two groups.
Findings: After two weeks of follow-up, the oxygen saturation and the respiratory rate significantly improved in the melatonin group. Moreover, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), lactate dehydrogenase (LDH), creatine phosphokinase (CPK), Ferritin, and D-Dimer levels significantly decreased in the melatonin group, but there was a considerable increase in the placebo group. Between-group comparison showed a significant difference between melatonin and placebo groups.
Interpretation: The results of this randomized, double-blind, placebo-controlled trial indicated the high efficacy and safety of melatonin as an adjuvant therapy in patients with mild to moderate COVID-19 disease. Further study with large sample size and on other populations like severe COVID-19 is recommended.
Trial Registration: This study is also registered in the Iranian Registry of Clinical Trials (IRCT registration number: IRCT20200408046988N1). Study protocol link: https://en.irct.ir/trial/47142.
Funding: This article was sponsored by the Research Council of Gonabad University of Medical Sciences (Gonabad, Iran)
Declaration of Interest: None to declare.
Ethical Approval: The ethics committee of Gonabad University of Medical Sciences approved the protocol of this study (Code: IR.GMU.REC.1399.016)
Suggested Citation: Suggested Citation